Prognosis
‘Bubble Boy’ Biotech Soars 250 Percent After Cure Announcement
This article is for subscribers only.
Shares of the tiny biotechnology company Mustang Bio Inc. more than tripled Thursday, following a scientific breakthrough that cured eight infants suffering from the devastating “Bubble Boy” immune system disorder.
Mustang Bio, backed by health-care serial entrepreneur Lindsay Rosenwald, has licensed the treatment for the rare disease from St. Jude Children’s Research Hospital, where the treatments took place.